Japan· JP-4291476A3020
モスネツズマブ（遺伝子組換え）
A mosunetuzumab product containing モスネツズマブ（遺伝子組換え）, registered in Japan by 中外製薬, on the national reimbursement list. The same ATC class is registered in 12 of our 19 countries.
Checked against MHLW / PMDA (Japan) on
Informational only — not a medical device.
Where it is registered
Mosunetuzumab is registered in 12 of 19 countries.
Countries holding a registration under ATC L01FX25 (mosunetuzumab), each read from that country’s own register.
- This record: Japan, from MHLW / PMDA (Japan)
- 7 of them publish a price we can compare per daily dose
Mosunetuzumab · ATC L01FX25
12 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
MHLW / PMDA (Japan)- Active substance
- モスネツズマブ（遺伝子組換え）
- Manufacturer
- 中外製薬
- Country
- Japan (JP)
- ATC code
- L01FX25
- ATC class
- Mosunetuzumab
- Defined daily dose
- 1.8 mg, P
- Reimbursed
- Yes
- Source register
- MHLW / PMDA (Japan)
- Last checked
- September 25, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Mosunetuzumab in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesLunsumioGenentech, Inc.
- FinlandLunsumioRoche Registration GmbH
- CzechiaLUNSUMIORoche Registration GmbH, Grenzach-Wyhlen
- SpainLUNSUMIO 1 MG CONCENTRADO PARA SOLUCION PARA PERFUSIONRoche Registration Gmbh
- BelgiumLunsumio 1 mgRoche Registration
- IcelandLunsumioRoche Registration GmbH*
- IrelandLunsumio 1 mg concentrate for solution for infusionRoche Registration GmbH
- SwitzerlandLunsumio 1 mg/1 ml, Konzentrat zur Herstellung einer InfusionslösungRoche Pharma (Schweiz) AG
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Lunsumio
- Liechtenstein · Lunsumio
- Norway · Lunsumio
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of MHLW / PMDA (Japan). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/dcc537f0-3913-4ff8-85bb-2880fc753a56 GET /v1/drugs/dcc537f0-3913-4ff8-85bb-2880fc753a56?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"spec": "５ｍｇ０．５ｍＬ１瓶",
"marks": null,
"source": "mhlw",
"remarks": null,
"yj_code": "4291476A3020",
"category": "注射薬",
"price_yen": 2540,
"generic_name": "モスネツズマブ（遺伝子組換え）",
"product_name_jp": null,
"therapeutic_class": "4291",
"transitional_expiry": "2540"
}See everything about mosunetuzumab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.